[Blockade of the renin-angiotensin-aldosterone system in Graves' disease].
García
José Luis Cabrerizo
JL
Etayo
Begoña Zalba
BZ
Calvo
Juan I Pérez
JI
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002302:Cardiac Output / Q000502:physiology; D005260:Female; D006111:Graves Disease / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D006331:Heart Diseases / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D018828:Immunoglobulins, Thyroid-Stimulating / Q000097:blood / Q000276:immunology / Q000502:physiology*; D008297:Male; D009318:Natriuresis / Q000502:physiology; D011989:Receptors, Thyrotropin / Q000276:immunology / Q000502:physiology; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*; D014284:Triiodothyronine / Q000502:physiology; D014655:Vascular Resistance / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D018828:Immunoglobulins, Thyroid-Stimulating; D011989:Receptors, Thyrotropin; C094372:thyrotropin-binding inhibitory immunoglobulin; D014284:Triiodothyronine